CA-RIPPLE
6.10.2020 09:02:14 CEST | Business Wire | Press release
Lemonway , the pan-European payment solution for online marketplaces, has today announced a partnership with Ripple , the enterprise blockchain solution for global payments, to enable instant, more transparent and cost-effective European transactions. Through RippleNet, Ripple’s global financial payments network, Lemonway will transform its euro-to-euro payouts which currently make up 80% of its payments volume.
Today, Lemonway’s robust payment processing platform is trusted and used by over 1,400 marketplaces in Europe including 200 crowdfunding platforms. Yet, as it scales, the company finds it needs to increasingly manage large volumes of transactions across multiple merchants and regions across Europe. This creates complexity in managing finances and often leads to delays of up to one week for payouts and settlements.
By turning to RippleNet, Lemonway can use blockchain technology to directly address these operational and complexity challenges, all the while delivering a competitive advantage over its peers. Blockchain technology, like that available on RippleNet, can provide payment providers supporting marketplaces with a more transparent, reliable and efficient way to process payments. It can perform instant payouts, which allows marketplaces to offer more competitive payment services to merchants.
Today’s partnership will see Lemonway improve its euro-to-euro payment corridors thanks to Nium ’s global money transfer network, that spans across over 100 markets, 65 in real-time, and utilizes RippleNet for its speed, transparency and cost-efficiency. While the initial focus is on euro-to-euro payments, this could be expanded to other currencies and corridors in the future.
“As a company that embraces innovation, we are always looking for new business models and technological capabilities that can enable us to offer better services to the marketplaces we serve and specifically their beneficiaries,” said Martin-Pierre Gaultier, Chief Commercial & Marketing Officer at Lemonway. “Our partnership with Ripple is a testament to this, and we’re excited to be able to offer faster and more cost-effective payouts to support the evolving needs of our customers and their platforms.”
“Our partnership with Lemonway is another significant endorsement of blockchain technology and its power to transform global payments,” said Asheesh Birla, GM of RippleNet. “In today’s competitive payments climate, technology makes the difference in delivering the best customer experience, and we are thrilled to be Lemonway’s trusted provider of instant and cost-effective B2B payment solutions to help them achieve that.”
About Lemonway
Lemonway offers a regulated payment solution dedicated to marketplaces, crowdfunding platforms requiring payment services on behalf of third parties within a secure and regulated framework (KYC, anti-fraud…). Lemonway was licensed by the ACPR/Banque de France as a Payment Institution in 2012 and has a financial passport in 29 countries. The fintech is based in Paris (HQ), London, Madrid, Milan and employs 90 people representing 16 different nationalities.
About Ripple
Ripple enables payments everywhere, every way, for everyone using the power of blockchain. By joining Ripple’s growing, global network (RippleNet), financial institutions can process their customers’ payments anywhere in the world instantly, reliably and cost-effectively. Banks and payment providers can use the digital asset XRP to further reduce their costs and access new markets. With offices in San Francisco, Washington D.C., New York, London, Mumbai, Singapore, São Paulo, Reykjavik and Dubai, Ripple has more than 300 customers around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
